Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | BMEA |
---|---|---|
09:32 ET | 7854 | 9 |
09:34 ET | 3900 | 8.89 |
09:36 ET | 1810 | 8.8959 |
09:39 ET | 1709 | 8.91 |
09:41 ET | 5400 | 9.01 |
09:43 ET | 1524 | 9.01 |
09:45 ET | 5663 | 9.071 |
09:48 ET | 26789 | 9.05 |
09:50 ET | 735 | 8.95 |
09:52 ET | 900 | 9.06 |
09:54 ET | 858 | 9.04 |
09:56 ET | 1542 | 9.03 |
09:57 ET | 876 | 8.99 |
09:59 ET | 342 | 8.92 |
10:01 ET | 100 | 8.94 |
10:03 ET | 3950 | 9.01 |
10:06 ET | 200 | 9.06 |
10:08 ET | 200 | 8.99 |
10:10 ET | 280 | 8.985 |
10:14 ET | 1336 | 8.88 |
10:15 ET | 400 | 8.905 |
10:17 ET | 1621 | 8.85 |
10:19 ET | 728 | 8.92 |
10:21 ET | 309 | 8.87 |
10:24 ET | 200 | 8.915 |
10:26 ET | 200 | 8.92 |
10:28 ET | 267 | 8.92 |
10:30 ET | 100 | 8.91 |
10:32 ET | 587 | 8.93 |
10:33 ET | 300 | 8.9 |
10:35 ET | 100 | 8.87 |
10:37 ET | 400 | 8.8683 |
10:44 ET | 100 | 8.845 |
10:46 ET | 307 | 8.85 |
10:48 ET | 1229 | 8.86 |
10:50 ET | 125 | 8.83 |
10:53 ET | 550 | 8.82 |
10:55 ET | 300 | 8.81 |
10:57 ET | 200 | 8.72 |
11:00 ET | 1079 | 8.78 |
11:02 ET | 872 | 8.76 |
11:04 ET | 3927 | 8.81 |
11:06 ET | 416 | 8.87 |
11:08 ET | 100 | 8.86 |
11:09 ET | 100 | 8.89 |
11:11 ET | 508 | 8.905 |
11:13 ET | 388 | 8.886 |
11:18 ET | 400 | 8.935 |
11:20 ET | 200 | 8.92 |
11:22 ET | 300 | 8.93 |
11:24 ET | 622 | 8.96 |
11:27 ET | 100 | 8.97 |
11:29 ET | 250 | 8.91 |
11:31 ET | 100 | 8.935 |
11:36 ET | 4101 | 8.93 |
11:42 ET | 12112 | 9.05 |
11:44 ET | 100 | 9.01 |
11:45 ET | 7587 | 9.05 |
11:47 ET | 4542 | 9.085 |
11:49 ET | 5255 | 9.0138 |
11:51 ET | 100 | 8.99 |
11:54 ET | 711 | 8.995 |
11:56 ET | 400 | 9 |
11:58 ET | 1000 | 8.92 |
12:02 ET | 265 | 8.94 |
12:05 ET | 300 | 8.96 |
12:09 ET | 200 | 8.91 |
12:12 ET | 300 | 8.92 |
12:14 ET | 202 | 8.83 |
12:16 ET | 1098 | 8.81 |
12:23 ET | 1152 | 8.8 |
12:25 ET | 1900 | 8.8 |
12:27 ET | 100 | 8.82 |
12:30 ET | 564 | 8.83 |
12:32 ET | 100 | 8.815 |
12:34 ET | 200 | 8.82 |
12:38 ET | 200 | 8.83 |
12:43 ET | 200 | 8.82 |
12:45 ET | 300 | 8.82 |
12:50 ET | 1800 | 8.82 |
12:52 ET | 600 | 8.82 |
12:59 ET | 500 | 8.77 |
01:06 ET | 4777 | 8.77 |
01:08 ET | 886 | 8.77 |
01:12 ET | 6025 | 8.75 |
01:14 ET | 300 | 8.73 |
01:15 ET | 100 | 8.76 |
01:17 ET | 600 | 8.74 |
01:19 ET | 1998 | 8.75 |
01:21 ET | 1165 | 8.7822 |
01:24 ET | 255 | 8.785 |
01:26 ET | 500 | 8.81 |
01:28 ET | 1600 | 8.7201 |
01:30 ET | 800 | 8.76 |
01:32 ET | 1250 | 8.72 |
01:33 ET | 400 | 8.73 |
01:35 ET | 2700 | 8.72 |
01:37 ET | 800 | 8.75 |
01:39 ET | 700 | 8.75 |
01:42 ET | 600 | 8.75 |
01:44 ET | 900 | 8.75 |
01:46 ET | 1601 | 8.81 |
01:50 ET | 200 | 8.815 |
01:51 ET | 300 | 8.835 |
01:53 ET | 525 | 8.87 |
01:55 ET | 1200 | 8.8033 |
01:57 ET | 500 | 8.8182 |
02:00 ET | 300 | 8.84 |
02:02 ET | 47343 | 9.135 |
02:04 ET | 486340 | 9.48 |
02:06 ET | 300724 | 9.61 |
02:08 ET | 115311 | 9.4 |
02:09 ET | 87238 | 9.3676 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Biomea Fusion Inc | 317.6M | -2.4x | --- |
Alto Neuroscience Inc | 316.8M | --- | --- |
Korro Bio Inc | 320.3M | -1.1x | --- |
Aldeyra Therapeutics Inc | 320.9M | -8.5x | --- |
Inozyme Pharma Inc | 323.1M | -3.5x | --- |
Corvus Pharmaceuticals Inc | 325.3M | -11.5x | --- |
Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of oral covalent small molecules to treat patients with metabolic diseases and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. The Company is utilizing its proprietary FUSION System to discover, design and develop a pipeline of covalent-binding small molecule medicines designed to maximize clinical benefit for patients. Its lead product candidate, BMF-219, is designed to be an oral, potent, and selective covalent inhibitor of menin, built from its FUSION System. It is developing BMF-219 for the treatment of menin regulated or dependent diseases, such as type 1 and type 2 diabetes as well as subtypes of liquid and solid tumors. Its second development candidate, BMF-500, a covalent inhibitor of activating mutations of the FMS-like tyrosine kinase 3 (FLT3).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $317.6M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 36.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.49 |
EPS | $-3.90 |
Book Value | $4.72 |
P/E Ratio | -2.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.